Holen Sie sich die Stockscreener-App
9.68
5.38%
-0.55
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Law firms investigate Immix Biopharma after executive termination - scanx.trade
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock - Investing News Network
Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock - TradingView
Immix Biopharma closes $117.1m stock offering - Investing.com
Immix Biopharma Closes $125 Million Stock Offering - marketscreener.com
Immix Biopharma closes $117.1m stock offering By Investing.com - Investing.com Nigeria
Immix Biopharma Closes $117.1 Million Underwritten Registered Offering - Quiver Quantitative
Citizens reiterates Immix Biopharma stock rating on trial data - Investing.com
Immix Bio offering to raise USD 125m after 89% CR rate for BCMA CAR T in amyloidosis - AllSci
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock - Yahoo Finance
Needham maintains Buy rating on Immix Biopharma, $30 price target - TradingView
Form 8K Immix Biopharma Inc For: 29 September By Investing.com - Investing.com Nigeria
Needham initiates coverage on Immix Biopharma with Buy rating - scanx.trade
Immix Biopharma prices $125M stock offering at $11.00 per share - scanx.trade
IMMX: NXC-201 delivers rapid, deep, and durable responses with strong safety in AL amyloidosis - TradingView
Transcript : Immix Biopharma, Inc.Shareholder/Analyst Call - marketscreener.com
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial - Yahoo Finance
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock - Investing News Network
Immix posts new trial data for AL amyloidosis drug (IMMX) - Seeking Alpha
Form 424B5 Immix Biopharma Inc For: 29 September By Investing.com - Investing.com Nigeria
Immix Biopharma prices $125M stock offering at $11 per share - Investing.com Nigeria
Immix Biopharma Prices $125 Million Stock Offering - marketscreener.com
Immix Biopharma reports 89% complete response rate in trial By Investing.com - Investing.com Nigeria
Immix Biopharma reports promising interim Phase 2 results - TipRanks
Immix Biopharma prices $125M stock offering - TradingView
IMMX: Interim results show an 89% complete response rate in AL Amyloidosis, with potential to reach 98% - TradingView
All 25 new patients had a complete response or tested negative for remaining disease - Stock Titan
Immix plans to use about $117 million for treatment development and company operations - Stock Titan
IMMX News | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
Immix Biopharma, Inc.(NasdaqCM: IMMX) added to S&P Global BMI Index - marketscreener.com
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Top BioTech SMidcap Stock: Mizuho Analyst Highlights IMMX By Investing.com - Investing.com South Africa
Mizuho raises Immix Biopharma stock price target to $26 on expansion By Investing.com - Investing.com South Africa
Mizuho raises Immix Biopharma stock price target to $26 on expansion - Investing.com India
IMMX: NXC-201 shows strong efficacy and safety in AL amyloidosis, with pivotal data and BLA submission ahead - TradingView
IMMX: NXC-201 demonstrates rapid, durable responses and strong safety in AL amyloidosis, advancing toward approval - TradingView
Immix Biopharma at Morgan Stanley conference: CAR T push gains pace - Investing.com Canada
Immix Biopharma (IMMX) Holds at $13.77: Biotech Stock Navigates Tight Trading RangeBeta Neutral Pair - dars.gov.et
IMMX Q2 2026 Earnings: Modest EPS Miss Signals Continued Clinical-Stage InvestmentEarnings Yield Analysis - dars.gov.et
Immix (IMMX) Today: Moves 1.32% Lower to $13.48 at the Close; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Available RecordUp Down Volume - vinanet.vn
Immix (IMMX) Latest: Ends Higher by 3.80% at $13.66 in Latest Trading; Technical View: the Price Remains Bounded by the Supplied Support and Resistance in Latest TradingBullish Pattern Stocks - dars.gov.et
Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat
Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat
Immix (IMMX) Quarterly Scorecard: The Available Figures Are Largely in Line on the Day; Session Move: Shares Fall 1.21% in the Current UpdatePre-Earnings Setup - vinanet.vn
Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month HighStill a Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX) - The Globe and Mail
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire
Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat
HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - marketscreener.com
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):